Indeed, according to interim results from this trial, the efficacy of combined Osimertinib and Savolitinib in the subgroup of patients with a high-level MET amplification (defined by the authors as MET-GCN ≥10 by FISH with Vysis MET FISH Probe Kit, Abbott Molecular, Inc.)and MET overexpression (defined as IHC 3+ in ≥90% of tumor cells with the MET SP44 RxDx Assay by Ventana Medical Systems, Inc.)was improved in terms of ORR 49% and mPFS 7.1 months, as compared with the overall population (with IHC 3+ in ≥50% and/or MET-GCN ≥5 by FISH) showing an ORR of 32% and mPFS 5.3 months. Here, MET is linked to neoplasm.